NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.
TypePublic
HQEdinburgh, GB
Founded2008
Size (employees)21 (est)+5%
Websitenucanabiomed.com
NuCana was founded in 2008 and is headquartered in Edinburgh, GB
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at NuCana

Hugh Griffith

Hugh Griffith

CEO
Ian Abercrombie

Ian Abercrombie

COO
Chris Wood

Chris Wood

Executive Chairman
Show more

NuCana Office Locations

NuCana has offices in Newton and Edinburgh
Edinburgh, GB (HQ)
10 Lochside Place
Newton, US
Riverside Center 275 Grove St
Show all (2)
Report incorrect company information

NuCana Financials and Metrics

NuCana Revenue

GBP

Net income (FY, 2017)

(23.1 m)

EBITDA (FY, 2017)

(25.6 m)

EBIT (FY, 2017)

(25.7 m)

Market capitalization (20-Sep-2018)

756.5 m

Closing stock price (20-Sep-2018)

23.8

Cash (31-Dec-2017)

86.7 m
NuCana's current market capitalization is $756.5 m.
GBPFY, 2014FY, 2015FY, 2016FY, 2017

Operating expense total

3.8 m6.9 m9 m

EBITDA

(6.9 m)(8.3 m)(25.6 m)

EBIT

(6.9 m)(8.4 m)(25.7 m)

Pre tax profit

(3.7 m)(6.5 m)(8.2 m)(25.5 m)
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2 2 2 2 2 2 2 2 117.1 k3.2 k759.2 k1 m6.4 m4.9 m36.4 m29.2 m20 m86.7 m

Accounts Receivable

42.3 k17.3 k185.8 k385.2 k561.8 k511.7 k639.5 k148.8 k21 k

Inventories

365.7 k

Current Assets

2 2 2 2 2 2 2 2 159.4 k386.1 k945 k1.4 m6.9 m5.4 m37.1 m30.7 m25.8 m94 m
GBPFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(3.1 m)(5.3 m)(6 m)(23.1 m)

Depreciation and Amortization

43.5 k101 k

Accounts Payable

133.1 k220 k

Cash From Operating Activities

(2.6 m)(4.5 m)(9.3 m)(8.7 m)
GBPY, 2017

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

NuCana Online and Social Media Presence

Embed Graph
Report incorrect company information

NuCana News and Updates

NuCana to Participate in Citi’s 13th Annual Biotech Conference

EDINBURGH, United Kingdom, Aug. 29, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial …
Report incorrect company information

NuCana Company Life and Culture

Report incorrect company information